AM-Pharma develops ilofotase alfa as a potential enzyme replacement therapy for adult hypophosphatasia (HPP) patients.
AM-Pharma has raised €12M across 1 funding round from 4 investors, most recently a Series D+ round in Sep 2014. Based in Utrecht, Netherlands; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2014-09-01 | Series D+ |
| €12M |
| Abbvie Biotech Ventures,Gilde Healthcare,Inventages Venture Capital,Ysios Capital |
| View deal → |
